Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T21:40:41.716Z.
Calculation as of: 2026-10-06T21:40:41.716Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92c64d45da0f6188a1f90128b536bb11be3c3b1eef81eadefd65dadb391e1e70
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$5.21M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.24M
PS Ratio
1.24
TTM Avg
1.37
3Y Avg
1.98
5Y Avg
32.27
Market Cap
$4.97M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.21M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | N/A | 1549.76 | 519.51 | 312.87 |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | 1.24 | 1.37 | 1.98 | 32.27 |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | 244.64 | 372.81 | 372.81 | 372.81 |
| Soligenix, Inc. (SNGX)vs › | $5.31M | N/A | 41.56 | 161.30 | 129.34 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | 27.60 | 40.33 | 58.43 | 54.62 |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | N/A | N/A | N/A | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | 1.49 | 1.97 | 2.19 | 4.13 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-10-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-09 |
| Q3 FY2026Period ended 2026-01-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-11 |
| Q4 FY2026Period ended 2026-04-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-22 |
| Q1 FY2027Period ended 2026-07-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-10 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
